Apogee Therapeutics initiated with a Buy at Citi
Citi initiated coverage of Apogee Therapeutics (APGE) with a Buy rating and $95 price target Healthcare policy remains a key biopharma sector ...
Yahoo Finance9d
Apogee Therapeutics, Inc. (APGE)
On Monday, Apogee Therapeutics, Inc. (NASDAQ:APGE) released interim Phase 1 results from its first-in-human trial of APG990. APG990 interim Phase 1 pharmacokinetic (PK) data showed a half-life of ...